Amgen’s Impressive Quarterly Performance Fuels Investor Confidence
Published on 11/06/2025 at 14:27 | Redaktion boerse-global.de
Amgen has delivered a standout quarterly performance that has captured significant market attention. The biotechnology leader not only surpassed investor expectations but also upgraded its full-year guidance, signaling robust operational momentum. The question now is whether this pharmaceutical giant can sustain this impressive trajectory.
The company’s financial foundation appears stronger than ever. Amgen generated a substantial $4.2 billion in free cash flow during the quarter, representing a 27% increase, while simultaneously reducing its debt load by $1.6 billion. This financial discipline coincides with aggressive investment in future growth, as research and development expenditures surged 31% to $1.9 billion. A key driver of this R&D expansion is the closely watched MariTide obesity study, Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
